A row of human samples for analytical testing including blood
Our Work

Latham & Watkins Advises on Gilead’s US$2 Billion Senior Unsecured Notes Offering

September 8, 2023
Interdisciplinary team represents the underwriters in the offering by the biopharmaceutical company.

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company, has announced the pricing of senior unsecured notes in an aggregate principal amount of US$2 billion, in an underwritten, registered public offering, consisting of US$1 billion of 5.250% senior notes maturing in 2033 and US$1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close September 14, 2023, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York/Los Angeles partner Greg Rodgers and Washington, D.C./New York partner Chuck Cassidy, with associates Catherine Shaw and Karysa Norris. Advice was also provided on tax matters by New York partner Bora Bozkurt, with associate Claire Park; on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with associate Robert Yeh; on data privacy matters by Bay Area partner Heather Deixler; on FDA regulatory matters by Washington, D.C. of counsel Carolyne Hathaway, with associate Emily Sachs; on healthcare regulatory matters by Bay Area partner Betty Pang; EU/UK regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with associates Jeanne Fabre and Ranulf Barman; on export control matters by Washington, D.C. counsel Ruchi Gill, with associate Elliot Hecht; and on anti-corruption matters by Washington, D.C. partner Kevin Chambers.